Aganitha
Bangalore, India· Est.
AI‑powered in‑silico platform accelerating multi‑modal drug discovery for biopharma.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
AI‑powered in‑silico platform accelerating multi‑modal drug discovery for biopharma.
OncologyImmunologyRare DiseasesCNS DisordersConsumer Care
Technology Platform
Agentic AI platform that integrates generative deep‑learning models with high‑throughput omics, structural biology, and computational chemistry to autonomously design and evaluate therapeutic candidates.
Opportunities
Expanding AI‑driven drug discovery services to early‑stage biopharma and leveraging multi‑modal capabilities to capture emerging therapeutic areas such as gene and RNA therapies.
Risk Factors
Reliance on rapidly evolving AI models and the need to prove downstream R&D impact; regulatory uncertainty around AI‑generated drug candidates.
Competitive Landscape
Competes with AI discovery‑discovery firms like Insilico Medicine, Exscientia, and Recursion; differentiates through its agentic AI workflow orchestration and focus on multi‑modal therapeutic design.